Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Intratumoral bacteria may elicit chemoresistance by metabolizing anticancer agents.

Literature DB >> 29404397

Intratumoral bacteria may elicit chemoresistance by metabolizing anticancer agents.

Abstract

We recently reported that bacteria can be found within pancreatic ductal adenocarcinoma (PDAC) tumors. Some of these bacteria can metabolize and thereby inactivate the nucleoside analog gemcitabine. We demonstrated that the long isoform of the bacterial enzyme cytidine deaminase (CDD) mediates the metabolism of gemcitabine. The clinical effect of overcoming this potential mechanism of drug resistance has yet to be studied.

Entities: Chemical Disease Gene

Keywords: PDAC; chemoresistance; drug metabolism; gemcitabine; mechanisms of resistance to therapy; mycoplasma; novel therapeutic targets; pancreatic ductal adenocarcinoma; tumor microbiome

Year: 2017 PMID： 29404397 PMCID： PMC5791857 DOI： 10.1080/23723556.2017.1405139

Source DB: PubMed Journal: Mol Cell Oncol ISSN： 2372-3556

10 in total

1. KEGG: kyoto encyclopedia of genes and genomes.

Authors: M Kanehisa; S Goto
Journal: Nucleic Acids Res Date: 2000-01-01 Impact factor: 16.971

2. Bacterial inactivation of the anticancer drug doxorubicin.

Authors: Erin L Westman; Marc J Canova; Inas J Radhi; Kalinka Koteva; Inga Kireeva; Nicholas Waglechner; Gerard D Wright
Journal: Chem Biol Date: 2012-10-26

3. Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine.

Authors: Leore T Geller; Michal Barzily-Rokni; Tal Danino; Oliver H Jonas; Noam Shental; Deborah Nejman; Nancy Gavert; Yaara Zwang; Zachary A Cooper; Kevin Shee; Christoph A Thaiss; Alexandre Reuben; Jonathan Livny; Roi Avraham; Dennie T Frederick; Matteo Ligorio; Kelly Chatman; Stephen E Johnston; Carrie M Mosher; Alexander Brandis; Garold Fuks; Candice Gurbatri; Vancheswaran Gopalakrishnan; Michael Kim; Mark W Hurd; Matthew Katz; Jason Fleming; Anirban Maitra; David A Smith; Matt Skalak; Jeffrey Bu; Monia Michaud; Sunia A Trauger; Iris Barshack; Talia Golan; Judith Sandbank; Keith T Flaherty; Anna Mandinova; Wendy S Garrett; Sarah P Thayer; Cristina R Ferrone; Curtis Huttenhower; Sangeeta N Bhatia; Dirk Gevers; Jennifer A Wargo; Todd R Golub; Ravid Straussman
Journal: Science Date: 2017-09-15 Impact factor: 47.728

Review 4. Microenvironmental regulation of therapeutic response in cancer.

Authors: Florian Klemm; Johanna A Joyce
Journal: Trends Cell Biol Date: 2014-12-22 Impact factor: 20.808

Review 5. The microbiome in anti-cancer therapy.

Authors: Stavros Bashiardes; Timur Tuganbaev; Sara Federici; Eran Elinav
Journal: Semin Immunol Date: 2017-04-18 Impact factor: 11.130

Review 6. Gemcitabine: metabolism and molecular mechanisms of action, sensitivity and chemoresistance in pancreatic cancer.

Authors: Lucas de Sousa Cavalcante; Gisele Monteiro
Journal: Eur J Pharmacol Date: 2014-07-30 Impact factor: 4.432

7. The cytostatic activity of pyrimidine nucleosides is strongly modulated by Mycoplasma hyorhinis infection: Implications for cancer therapy.

Authors: Annelies Bronckaers; Jan Balzarini; Sandra Liekens
Journal: Biochem Pharmacol Date: 2008-05-04 Impact factor: 5.858

8. Nucleoside-catabolizing enzymes in mycoplasma-infected tumor cell cultures compromise the cytostatic activity of the anticancer drug gemcitabine.

Authors: Johan Vande Voorde; Suna Sabuncuoğlu; Sam Noppen; Anders Hofer; Farahnaz Ranjbarian; Steffen Fieuws; Jan Balzarini; Sandra Liekens
Journal: J Biol Chem Date: 2014-03-25 Impact factor: 5.157

9. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion.

Authors: Ravid Straussman; Teppei Morikawa; Kevin Shee; Michal Barzily-Rokni; Zhi Rong Qian; Jinyan Du; Ashli Davis; Margaret M Mongare; Joshua Gould; Dennie T Frederick; Zachary A Cooper; Paul B Chapman; David B Solit; Antoni Ribas; Roger S Lo; Keith T Flaherty; Shuji Ogino; Jennifer A Wargo; Todd R Golub
Journal: Nature Date: 2012-07-26 Impact factor: 49.962

10. Local bacteria affect the efficacy of chemotherapeutic drugs.

Authors: Panos Lehouritis; Joanne Cummins; Michael Stanton; Carola T Murphy; Florence O McCarthy; Gregor Reid; Camilla Urbaniak; William L Byrne; Mark Tangney
Journal: Sci Rep Date: 2015-09-29 Impact factor: 4.379

10 in total

13 in total

Intratumoral bacteria may elicit chemoresistance by metabolizing anticancer agents.

1. KEGG: kyoto encyclopedia of genes and genomes.

2. Bacterial inactivation of the anticancer drug doxorubicin.

3. Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine.

Review 4. Microenvironmental regulation of therapeutic response in cancer.

Review 5. The microbiome in anti-cancer therapy.

Review 6. Gemcitabine: metabolism and molecular mechanisms of action, sensitivity and chemoresistance in pancreatic cancer.

7. The cytostatic activity of pyrimidine nucleosides is strongly modulated by Mycoplasma hyorhinis infection: Implications for cancer therapy.

8. Nucleoside-catabolizing enzymes in mycoplasma-infected tumor cell cultures compromise the cytostatic activity of the anticancer drug gemcitabine.

9. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion.

10. Local bacteria affect the efficacy of chemotherapeutic drugs.

1. Microbial dysbiosis and polyamine metabolism as predictive markers for early detection of pancreatic cancer.

2. Mycoplasma hyorhinis infection promotes tyrosine kinase inhibitor (TKI) resistance in lung adenocarcinoma patients.

3. Microbiome in drug resistance to colon cancer.

Review 4. Gut Microbiome Modulates Response to Cancer Immunotherapy.

Review 5. Microbiome-Microbial Metabolome-Cancer Cell Interactions in Breast Cancer-Familiar, but Unexplored.

Review 6. Intestinal Microbiota: A Novel Target to Improve Anti-Tumor Treatment?

Review 7. Microbial markers in colorectal cancer detection and/or prognosis.

Review 8. The Interplay between Immunity and Microbiota at Intestinal Immunological Niche: The Case of Cancer.

Review 9. Role of the microbiome in occurrence, development and treatment of pancreatic cancer.

Review 10. Commensal microbes and p53 in cancer progression.